2022-RA-627-ESGO Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer

Abstract

2022-RA-627-ESGO Figure 1 Waterfall plot of validated somatic mutations in the patient tumors. Genes are indicated in rows and samples in columns. Mutated samples are show according to mutation type. Patient and tumor clinopathological variables are shown below the patient IDs Abstract 2022-RA-627-ESGO Figure 2 Plasma circulating tum or (ctDNA) mutant concentration increased with higher stage (ptrend<0.001).Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa (p=0.025 and p=0.007 respectively) Bars include highest and lowest values, except outliers (o), which are 1.5 to 3 box lengths from the end of the box, and extremes (*) which are more than 3 box lengths from the end of the box2022-RA-627-ESGO Figure 2 Plasma circulating tum or (ctDNA) mutant concentration increased with higher stage (ptrend<0.001).Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa (p=0.025 and p=0.007 respectively) Bars include highest and lowest values, except outliers (o), which are 1.5 to 3 box lengths from the end of the box, and extremes (*) which are more than 3 box lengths from the end of the box Conclusion Measuring ctDNA in pre-operative plasma may be useful as a predictive biomarker for tumor staging and prognosis in ovarian cancer patients. Abstracts Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504 A405 on D ecem er 8, 2022 by gest. P rocted by coright. http/ijgc.bm jcom / nt J G ynecol C acer: frst pulished as 10.11ijgc-2022-E S G O .68 on 20 O cber 222. D ow nladed fom